Transdermal Adhesive Matrix for Donepezil Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal delivery systems for donepezil face challenges due to poor skin permeability and low solubility of the drug in adhesives, leading to instability and ineffective long-term administration, particularly for cognitive disorders like Alzheimer's disease.
Innovation Solution
A composition for transdermal delivery of donepezil is developed, comprising an adhesive matrix with 5-50 wt% donepezil free base, 5-50 wt% adhesive polymer, 5-40 wt% solubility enhancer (ester of a dicarboxylic acid), and 1-20 wt% lipophilic permeation enhancer, including fatty acids and keto carboxylic acids, to enhance solubility and skin penetration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If donepezil is formulated in a transdermal adhesive system, then long-term delivery is achieved, but solubility in the adhesive matrix is poor
Solution Approach 1:
The patent employs solubility enhancers and permeation enhancers as intermediary substances to bridge the incompatibility between donepezil and the adhesive matrix. These enhancers facilitate drug dissolution and skin penetration without requiring the drug to be inherently soluble in the adhesive, thus resolving the contradiction between long-term delivery capability and poor solubility.
Solution Approach 2:
The patent modifies the chemical parameters of the formulation by incorporating specific solubility enhancers (such as esters of dicarboxylic acids) and permeation enhancers (such as fatty acids and keto carboxylic acids). These parameter changes enable donepezil to achieve adequate solubility and permeability in the transdermal system while maintaining long-term delivery functionality.
2Object-affected harmful factors
If donepezil is delivered transdermally, then gastrointestinal adverse effects are reduced, but skin permeability is poor
Solution Approach 1:
Lipophilic permeation enhancers serve as mediators that facilitate donepezil's passage through the skin barrier. These substances temporarily modify the skin's permeability properties, allowing the drug to penetrate effectively without compromising the gastrointestinal benefits of transdermal delivery.
Solution Approach 2:
The patent utilizes permeation enhancers including fatty acids, α-hydroxy acids, β-hydroxy acids, and keto carboxylic acids to dynamically alter the skin's permeation parameters. These enhancers temporarily change the skin barrier properties to allow donepezil passage while maintaining the overall safety profile of transdermal administration.
3Ease of operation
If donepezil is administered orally, then patient compliance is easier, but plasma fluctuations are frequent
Solution Approach 1:
The transdermal patch is applied in advance and continuously delivers donepezil through the skin, eliminating the need for repeated oral dosing. This preliminary action of applying a single patch provides sustained drug release over multiple days, ensuring both patient compliance and stable plasma levels without the fluctuations associated with oral administration.
Solution Approach 2:
The patent implements continuous transdermal delivery of donepezil through the adhesive matrix, which maintains a steady supply of the drug to the bloodstream. This continuous action contrasts with the intermittent oral dosing that causes plasma fluctuations, thereby achieving both ease of use and compositional stability.
4Duration of action of stationary object
If basic drugs like donepezil are delivered transdermally, then long-term administration is achieved, but skin permeability remains poor
Solution Approach 1:
The patent uses lipophilic permeation enhancers as intermediary agents that specifically address the poor permeability of basic drugs through the skin. These enhancers facilitate the passage of protonated basic drugs like donepezil by interacting with the skin barrier, enabling long-term transdermal administration that would otherwise be ineffective.
Solution Approach 2:
The formulation incorporates permeation enhancers that temporarily modify the skin's permeation parameters for basic drugs. These enhancers change the local chemical environment at the skin interface, allowing basic drugs with poor inherent permeability to achieve effective transdermal delivery over the long term.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides stable and effective long-term transdermal delivery of donepezil, improving solubility and skin permeability, thereby enhancing therapeutic efficacy and patient compliance for cognitive disorder treatments.
Implementation Method 1
5-40 wt% of at least one solubility enhancer that is an ester of a dicarboxylic acid
Implementation Method 2
1-20 wt% of at least one lipophilic permeation enhancer that is selected from a fatty acid, an α-hydroxy acid, a β-hydroxy acid, and a keto carboxylic acid
Data Source
Figure 1A~1B
AI summary
Methods, compositions, and devices for transdermally administering an active agent such as donepezil are provided.